In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...
Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...
Tarpon Springs, Florida Monday, March 9, 2026, 15:00 Hrs [IST] ...
The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...
The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...
The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results